Ovid Therapeutics Inc. (OVID) Stock Grade

About Ovid Therapeutics Inc.'s fundamentals

Ovid Therapeutics is a biotechnology company with a market capitalization of $459.1 million that demonstrated exceptional revenue growth of 1,181.3% year-over-year, indicating rapid commercial expansion or product adoption. However, the company operates at a substantial loss, with a net margin of -240.1%, meaning it spent $2.40 for every dollar of revenue generated. The absence of profitability metrics like P/E ratio and return on equity, combined with the reported annual net loss, reflects the company's pre-profitability stage typical of development-focused biotech firms. There is no dividend yield, as the company is reinvesting resources into its operations rather than returning capital to shareholders.